10x Genomics Stock Today
| TXG Stock | USD 10.34 0.46 4.66% |
PerformanceVery Weak
| Odds Of DistressLow
|
10X Genomics is trading at 10.34 as of the 17th of March 2025. This is a 4.66 percent increase since the beginning of the trading day. The stock's lowest day price was 10.01. 10X Genomics has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. The company has 108.25 M outstanding shares of which 11.32 M shares are at this time shorted by investors with about 4.44 days to cover. More on 10X Genomics
Moving together with 10X Stock
Moving against 10X Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
10X Stock Highlights
10X Genomics (TXG) is traded on NASDAQ Exchange in USA. It is located in 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260 and employs 1,306 people. 10X Genomics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.26 B. 10X Genomics runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 108.25 M outstanding shares of which 11.32 M shares are at this time shorted by investors with about 4.44 days to cover.
10X Genomics has about 499.73 M in cash with 6.66 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39.
Check 10X Genomics Probability Of Bankruptcy
Ownership Allocation10X Genomics holds a total of 108.25 Million outstanding shares. The majority of 10X Genomics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 10X Genomics to benefit from reduced commissions. Hence, institutional investors are subject to a different set of regulations than regular investors in 10X Genomics. Please pay attention to any change in the institutional holdings of 10X Genomics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check 10X Ownership Details
10X Genomics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. 10X Genomics market risk premium is the additional return an investor will receive from holding 10X Genomics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | 0.1303 | |||
| Treynor Ratio | (16.78) |
10X Stock Against Markets
10X Genomics Corporate Management
| James Wilbur | Chief Officer | Profile | |
| Mennah Moustafa | Chief Officer | Profile | |
| Ruth Backer | Chief Officer | Profile | |
| Florian Baumgartner | Senior Manager | Profile | |
| Jonathan Schimmel | VP Operations | Profile | |
| Jim Goodrich | Chief Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.